International eye-care products manufacturer Allergan announced positive outcomes from the AbbVie company’s Phase 3 study of a new treatment for presbyopia, as the ophthalmic solution AGN-190584 met primary and key secondary endpoints.
https://www.pharmalive.com/wp-content/uploads/2021/07/Allergan-Eye-Drop-for-Presbyopia-Hits-All-Endpoints-Focuses-In-on-Approval-BioSpace-7-26-21.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-07-26 11:44:572021-07-26 12:44:10Allergan Eye Drop for Presbyopia Hits All Endpoints